This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Health Catalyst (HCAT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Health Catalyst (HCAT) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 33.33% and 1.21%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Time to Play 5 Top-Ranked Stocks With Rising P/E?
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Exagen (XGN), Health Catalyst (HCAT), CLEAR Secure (YOU) and Applied DNA Sciences (APDN).
Do Options Traders Know Something About Health Catalyst (HCAT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Health Catalyst (HCAT) stock based on the movements in the options market lately.
Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst
by Zacks Equity Research
Hims & Hers Health, Enovis Corp and Health Catalyst are part of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.
Why Health Catalyst (HCAT) Might be Well Poised for a Surge
by Zacks Equity Research
Health Catalyst (HCAT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts See a 75.19% Upside in Health Catalyst (HCAT): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 75.2% in Health Catalyst (HCAT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Health Catalyst (HCAT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Health Catalyst (HCAT) Q1 Earnings Beat Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 66.67% and 0.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Sonendo, Inc. (SONX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sonendo (SONX) delivered earnings and revenue surprises of -244.44% and 11.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Get a deeper insight into the potential performance of Health Catalyst (HCAT) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Definitive Healthcare Corp. (DH) Matches Q1 Earnings Estimates
by Zacks Equity Research
Definitive Healthcare (DH) delivered earnings and revenue surprises of 0% and 0.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat
by Zacks Equity Research
Humana (HUM) bumps up individual Medicare Advantage membership growth guidance.
Elevance (ELV) Q1 Earnings Beat on Rate Hikes, Guidance Raised
by Zacks Equity Research
Elevance Health (ELV) has a leftover capacity of around $3.6 billion under its share buyback authorization.
Acadia Healthcare (ACHC) Opens Facility to Address Mental Health
by Zacks Equity Research
Acadia Healthcare (ACHC) inaugurates an acute care hospital in Mesa, AZ, to cater to patients struggling with addiction and mental health issues in the area.
Brookdale Senior (BKD) Sees Y/Y Increase in Q1 Occupancy Levels
by Zacks Equity Research
Brookdale Senior (BKD) witnesses 29 straight months of year-over-year increases in weighted average occupancy level.
Down -24.71% in 4 Weeks, Here's Why You Should You Buy the Dip in Health Catalyst (HCAT)
by Zacks Equity Research
Health Catalyst (HCAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Compelling Reasons to Hold Acadia Healthcare (ACHC) Stock Now
by Zacks Equity Research
Growing commercial, Medicare and Medicaid revenues will likely boost Acadia Healthcare's (ACHC) top line.
Humana's (HUM) Medicaid Business Teams Up With CPESN USA in Ohio
by Zacks Equity Research
Humana's (HUM) partnership with CPESN USA in Ohio aims to overcome barriers like limited access to healthcare services in rural and underserved communities.
Select Medical (SEM) Expands in Florida With UF Health JV
by Zacks Equity Research
Select Medical (SEM) inks a joint venture agreement with UF Health Jacksonville to open a 48-bed inpatient rehabilitation hospital in Florida.
UnitedHealth's (UNH) Optum to Buy Steward's Physician Group
by Zacks Equity Research
UnitedHealth (UNH) unit Optum's acquisition of Steward Health's physician group is expected to close in the second quarter of 2024.
Wall Street Analysts Think Health Catalyst (HCAT) Could Surge 53.65%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Health Catalyst (HCAT) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
3 Medical Info Systems Stocks to Buy as Industry Improves
by Urmimala Biswas
A few Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Talkspace (TALK) and Health Catalyst (HCAT) are expected to gain from the new normal trends.
Select Medical's (SEM) Concentra Submits Confidential IPO Filing
by Zacks Equity Research
The move from Select Medical's (SEM) Concentra highlights the recovery in the U.S. IPO market, especially for healthcare companies.